Press coverage about Cambrex (NYSE:CBM) has trended somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cambrex earned a news sentiment score of 0.23 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 47.3068218299606 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:
- Cambrex Co. (CBM) Holdings Trimmed by Ranger Investment Management L.P. (americanbankingnews.com)
- Lazard Asset Management LLC Invests $22.20 Million in Cambrex Co. (CBM) (americanbankingnews.com)
- Cambrex Co. (CBM) Shares Sold by Bank of New York Mellon Corp (americanbankingnews.com)
- Cambrex Co. (CBM) Shares Sold by Kennedy Capital Management Inc. (americanbankingnews.com)
- Royce & Associates LP Has $4.30 Million Holdings in Cambrex Co. (CBM) (americanbankingnews.com)
CBM has been the subject of a number of analyst reports. Zacks Investment Research raised shares of Cambrex from a “strong sell” rating to a “hold” rating in a report on Monday, January 15th. William Blair initiated coverage on shares of Cambrex in a report on Tuesday, January 16th. They set an “outperform” rating for the company. Finally, Longbow Research downgraded shares of Cambrex from a “buy” rating to a “neutral” rating in a report on Wednesday, February 14th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $60.00.
Cambrex (NYSE:CBM) last announced its quarterly earnings results on Thursday, February 8th. The biotechnology company reported $1.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.17. Cambrex had a net margin of 19.17% and a return on equity of 22.42%. The firm had revenue of $182.28 million during the quarter, compared to the consensus estimate of $181.39 million. During the same period last year, the firm posted $1.23 EPS. The firm’s quarterly revenue was up 2.5% on a year-over-year basis. equities analysts predict that Cambrex will post 2.76 EPS for the current year.
TRADEMARK VIOLATION WARNING: This report was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://sportsperspectives.com/2018/03/10/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-cambrex-cbm-share-price.html.
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.